ENLV

Enlivex Therapeutics Ltd. [ENLV] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ENLV Stock Summary

In the News

ENLV Financial details

Company Rating
-
Market Cap
29.37M
Income
-29.5M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
71
Optionable
No
Shortable
Yes
Earnings
24 Jun 2024
P/E
-2.26
Forward P/E
-
PEG
0.73
P/S
-
P/B
1.57
P/C
-
P/FCF
-2.35
Quick Ratio
7.34
Current Ratio
7.34
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.59
EPS next Y
-
EPS next Q
-
EPS this Y
-32.47%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
53.13%
-
-
-
-
SMA20
-
SMA50
-9.92%
SMA100
-29.22%
Inst Own
-
Inst Trans
-
ROA
-57%
ROE
-57%
ROC
-0.63%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.2-4.59
52W High
-70.25%
52W Low
+19%
RSI
59.22
Rel Volume
3.57
Avg Volume
132.06K
Volume
470.82K
Perf Week
19%
Perf Month
0%
Perf Quarter
-25.16%
Perf Half Y
-6.3%
-
-
-
-
Beta
1.055
-
-
Volatility
0.07%, 0.06%
Prev Close
3.48%
Price
1.19
Change
8.18%

Something similar

Top by Market Cap
NVD.DE
GOOG
VTI
AMZN
TSLA
Same Sector
HTBX
BUDZ
ORINY
BFRA
VSBC
Same Price Range
XBAK.DE
1200.HK
GAN
8353.HK
E.TO
Similar Market Cap
ISHA.DE
SAGP
POXEL.PA
8482.HK
8228.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 132.06K
  • Market Capitalization 29.37M
  • Employee 71
  • CEO Dr. Oren Hershkovitz Ph.D.
  • Headquarters Ness Ziona,IL
  • IPO Date 2014-07-31
  • Website https://www.enlivex.com

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.